JP2024519031A5 - - Google Patents
Info
- Publication number
- JP2024519031A5 JP2024519031A5 JP2023571272A JP2023571272A JP2024519031A5 JP 2024519031 A5 JP2024519031 A5 JP 2024519031A5 JP 2023571272 A JP2023571272 A JP 2023571272A JP 2023571272 A JP2023571272 A JP 2023571272A JP 2024519031 A5 JP2024519031 A5 JP 2024519031A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- composition according
- group
- target
- moi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189503P | 2021-05-17 | 2021-05-17 | |
| US63/189,503 | 2021-05-17 | ||
| PCT/US2022/029533 WO2022245757A1 (en) | 2021-05-17 | 2022-05-17 | Compositions including conjugated therapy enhancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519031A JP2024519031A (ja) | 2024-05-08 |
| JP2024519031A5 true JP2024519031A5 (enExample) | 2025-05-23 |
Family
ID=84140038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571272A Pending JP2024519031A (ja) | 2021-05-17 | 2022-05-17 | コンジュゲート療法エンハンサーを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240238436A1 (enExample) |
| EP (1) | EP4351658A4 (enExample) |
| JP (1) | JP2024519031A (enExample) |
| KR (1) | KR20240012376A (enExample) |
| CN (1) | CN117295527A (enExample) |
| AU (1) | AU2022277840A1 (enExample) |
| BR (1) | BR112023023506A2 (enExample) |
| CA (1) | CA3219475A1 (enExample) |
| IL (1) | IL307746A (enExample) |
| MX (1) | MX2023013274A (enExample) |
| PH (1) | PH12023553152A1 (enExample) |
| WO (1) | WO2022245757A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026150353A2 (en) | 2025-01-11 | 2026-07-16 | Biohaven Therapeutics Ltd. | Antibody-drug conjugates for delivering cytotoxic agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017139329A1 (en) * | 2016-02-09 | 2017-08-17 | Alexander Krantz | Site-selective functionalization of proteins using traceless affinity lables |
| SG11202000628XA (en) * | 2017-07-26 | 2020-02-27 | Kleo Pharmaceuticals Inc | Universal abt compounds and uses thereof |
| CA3134610A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| WO2019241609A1 (en) * | 2018-06-15 | 2019-12-19 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
| CN120865350A (zh) * | 2019-01-23 | 2025-10-31 | 阿比蒂斯有限公司 | 用于制备抗体-载荷部分偶联物的化合物及其用途 |
| AU2020234394B2 (en) * | 2019-03-08 | 2024-02-15 | AbTis Co., Ltd. | Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof |
| KR20220103986A (ko) * | 2019-11-18 | 2022-07-25 | 클레오 파마슈티컬스 인코포레이티드 | 지정 접합 기술 |
| EP4069311A1 (en) * | 2019-12-03 | 2022-10-12 | Debiopharm Research & Manufacturing SA | Reactive conjugates |
| WO2022078566A1 (en) * | 2020-10-12 | 2022-04-21 | Debiopharm Research & Manufacturing S.A. | Reactive conjugates |
| JPWO2022080385A1 (enExample) * | 2020-10-13 | 2022-04-21 | ||
| WO2022192478A1 (en) * | 2021-03-10 | 2022-09-15 | Biohaven Therapeutics Ltd. | Bifunctional degraders of galactose-deficient immunoglobulins |
| IL307799A (en) * | 2021-05-17 | 2023-12-01 | Biohaven Therapeutics Ltd | Agents for targeted coupling techniques and conjugated products |
| EP4340859A4 (en) * | 2021-05-19 | 2025-07-02 | Biohaven Therapeutics Ltd | ANTIBODY-DRUG CONJUGATES USING COUPLING TECHNOLOGY TO DELIVER CYTOTOXIC AGENTS |
| WO2023043861A2 (en) * | 2021-09-16 | 2023-03-23 | Biohaven Therapeutics Ltd. | Conjugated antibodies for treating diseases |
-
2022
- 2022-05-17 PH PH1/2023/553152A patent/PH12023553152A1/en unknown
- 2022-05-17 IL IL307746A patent/IL307746A/en unknown
- 2022-05-17 KR KR1020237039153A patent/KR20240012376A/ko active Pending
- 2022-05-17 AU AU2022277840A patent/AU2022277840A1/en active Pending
- 2022-05-17 EP EP22805273.4A patent/EP4351658A4/en active Pending
- 2022-05-17 US US18/555,855 patent/US20240238436A1/en active Pending
- 2022-05-17 MX MX2023013274A patent/MX2023013274A/es unknown
- 2022-05-17 JP JP2023571272A patent/JP2024519031A/ja active Pending
- 2022-05-17 CN CN202280034211.XA patent/CN117295527A/zh active Pending
- 2022-05-17 WO PCT/US2022/029533 patent/WO2022245757A1/en not_active Ceased
- 2022-05-17 BR BR112023023506A patent/BR112023023506A2/pt unknown
- 2022-05-17 CA CA3219475A patent/CA3219475A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60206272T2 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| JP2024521092A5 (enExample) | ||
| JP2005507376A (ja) | ペプチドベースの化合物 | |
| JP6164556B2 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| JP2010174013A (ja) | 組織ダメージの治療と予防 | |
| WO2021080008A1 (ja) | １価ｃｃａｐ生成物の製造方法 | |
| JP2005531559A5 (enExample) | ||
| JP2023535026A5 (enExample) | ||
| JP2024509282A5 (enExample) | ||
| JP2018531287A5 (enExample) | ||
| JP2020509010A5 (enExample) | ||
| CA2372116A1 (en) | Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b) | |
| JP7249591B2 (ja) | 分解性ポリエチレングリコール結合体 | |
| JP3274225B2 (ja) | アミノ酸誘導体及びその用途 | |
| WO2015076359A1 (ja) | プロテアソーム阻害性化合物 | |
| DE69816241T2 (de) | Aktivierte peptide und konjugate | |
| CA3219517A1 (en) | Agents for directed conjugation techniques and conjugated products | |
| JP2003503465A (ja) | 分子間で会合した化合物とこれらの化合物を含む凝集体 | |
| US20240287131A1 (en) | Peptide | |
| JP7205827B2 (ja) | 分解性ポリエチレングリコール誘導体 | |
| US5763408A (en) | Amino acid derivatives and application thereof | |
| JP2023501720A5 (enExample) | ||
| AU2018208103A1 (en) | An agent for promoting angiogenesis and methods and uses thereof | |
| CN102282160B (zh) | 多配体构成物 | |
| TW202417465A (zh) | 環肽或其鹽及ｍｄｍｘ抑制劑 |